Allakos Inc. (NASDAQ:ALLK – Get Rating) – Stock analysts at Cantor Fitzgerald reduced their FY2022 EPS estimates for shares of Allakos in a research report issued on Thursday, May 19th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings per share of ($5.83) for the year, down from their previous estimate of ($5.29). Cantor Fitzgerald has a “Overweight” rating on the stock.
Several other equities analysts also recently weighed in on ALLK. Zacks Investment Research downgraded shares of Allakos from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 10th. SVB Leerink reduced their target price on shares of Allakos from $17.00 to $13.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 16th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $60.22.
Allakos (NASDAQ:ALLK – Get Rating) last posted its quarterly earnings data on Friday, May 6th. The company reported ($3.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($1.65).
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Credit Suisse AG boosted its holdings in shares of Allakos by 0.7% in the 3rd quarter. Credit Suisse AG now owns 27,019 shares of the company’s stock valued at $2,860,000 after buying an additional 188 shares in the last quarter. Arizona State Retirement System raised its position in Allakos by 2.2% during the 3rd quarter. Arizona State Retirement System now owns 8,755 shares of the company’s stock worth $927,000 after buying an additional 192 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in Allakos by 2.2% during the 3rd quarter. UBS Asset Management Americas Inc. now owns 35,031 shares of the company’s stock worth $3,709,000 after buying an additional 765 shares during the last quarter. CNA Financial Corp grew its stake in shares of Allakos by 16.4% during the 3rd quarter. CNA Financial Corp now owns 6,330 shares of the company’s stock worth $670,000 after purchasing an additional 890 shares during the period. Finally, Teacher Retirement System of Texas grew its stake in shares of Allakos by 23.4% during the 3rd quarter. Teacher Retirement System of Texas now owns 5,075 shares of the company’s stock worth $537,000 after purchasing an additional 961 shares during the period. Institutional investors own 61.07% of the company’s stock.
Allakos Company Profile (Get Rating)
Allakos Inc, a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
- Get a free copy of the StockNews.com research report on Allakos (ALLK)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.